Invasive pneumococcal disease in children under 60 months before and after availability of 13-valent conjugate vaccine
Por:
Johanna Martínez Osorio, García-García JJ, Moraga-Llop F, Díaz A, Hernández S, Solé-Ribalta A, González-Peris S, Izquierdo C, Esteva-Afonso C, Codina G, Planes AM, Uriona S, Campins M, Ciruela P, Salleras L, Domínguez Á, Munoz-Almagro C and Fernández de Sevilla-Estrach M
Publicada:
1 jun 2022
Ahead of Print:
1 jun 2022
Categoría:
Pediatrics, perinatology and child health
Resumen:
Background: Invasive pneumococcal disease (IPD) is the most important bacterial infection in young children, and the introduction of pneumococcal conjugate vaccines has changed its presentation. This study compared the incidence, characteristics and serotype distribution of IPD before and after the introduction of the pneumococcal conjugate vaccine (PCV13).
Methods: Prospective enrolment of patients with IPD aged less than 60 months and admitted to either of 2 tertiary care hospitals between January 2007 and December 2009 (pre-PCV13 period) and January 2012 and June-2016 (PCV13 period).
Results: We identified 493 cases, 319 in the pre-PCV13 period and 174 in the PCV13 period. The incidence of IPD decreased from 89.7 to 34.4 cases per 100,000 population (-62%; P< .001). This decrease was observed in all forms of disease except necrotising pneumonia (increase from 0.8 to 3.7 cases/100,000 population). There was a significant reduction in all serotypes included in the PCV13 and not included in the PCV7. We did not find significant differences in length of stay, mortality or the frequency of sequelae between both periods, but in the PCV13 period, the length of stay in the paediatric intensive care unit and the duration of mechanical ventilation were longer (P= .00). The incidence of serotype 3 decreased from 10.4 to 6.9 cases per 100,000 population, although it was the serotype involved most frequently in patients with severe disease.
Conclusions: After the introduction of the PCV13, there has been a significant decrease in IPD cases. Serotype 3 continues to be an important cause of severe IPD. (C) 2021 Asociacion Espanola de Pediatria. Published by Elsevier Espana, S.L.U.
Filiaciones:
Johanna Martínez Osorio:
Hospital Sant Joan de Deu, Barcelona, España
García-García JJ:
Malalties Prevenibles amb Vacunes, Institut de Recerca Sant Joan de Déu, Hospital Sant Joan de Déu, Universitat de Barcelona, Barcelona, España
Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Barcelona, España
Moraga-Llop F:
Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, España
Díaz A:
Hospital de Nens, Barcelona, España
Hernández S:
Agència de Salut Pública de Catalunya, Generalitat de Catalunya, Barcelona, España
Solé-Ribalta A:
Hospital Sant Joan de Deu, Barcelona, España
González-Peris S:
Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, España
Izquierdo C:
Agència de Salut Pública de Catalunya, Generalitat de Catalunya, Barcelona, España
Esteva-Afonso C:
Malalties Prevenibles amb Vacunes, Institut de Recerca Sant Joan de Déu, Hospital Sant Joan de Déu, Universitat de Barcelona, Barcelona, España
Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Barcelona, España
Codina G:
Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, España
Planes AM:
Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, España
Uriona S:
Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, España
Campins M:
Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, España
Ciruela P:
Agència de Salut Pública de Catalunya, Generalitat de Catalunya, Barcelona, España
Salleras L:
Departament de Medicina, Universitat de Barcelona, Barcelona, España
Domínguez Á:
Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Barcelona, España
Departament de Medicina, Universitat de Barcelona, Barcelona, España
Munoz-Almagro C:
Malalties Prevenibles amb Vacunes, Institut de Recerca Sant Joan de Déu, Hospital Sant Joan de Déu, Universitat de Barcelona, Barcelona, España
Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Barcelona, España
Departament de Medicina, Universitat Internacional de Catalunya, Barcelona, España
Fernández de Sevilla-Estrach M:
Malalties Prevenibles amb Vacunes, Institut de Recerca Sant Joan de Déu, Hospital Sant Joan de Déu, Universitat de Barcelona, Barcelona, España
Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Barcelona, España
gold
|